Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05182359 · ClinicalTrials.gov registry record · NA

Pragmatic Impact of Proteomic Risk Stratification in Diabetes Mellitus

A NA study of Type 2 Diabetes, sponsored by University Hospitals Cleveland Medical Center.

Completed
Registry status
NA
Development phase
150
Enrollment target
1
Study location

NCT05182359: Completed NA study of Type 2 Diabetes, sponsored by University Hospitals Cleveland Medical Center.

NCT05182359 is a NA study of Type 2 Diabetes that has completed, run by University Hospitals Cleveland Medical Center. The registered enrollment target is 150 participants, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05182359, a NA study of Type 2 Diabetes, has completed, sponsored by University Hospitals Cleveland Medical Center.

COMPLETED
Registry status
NA
Development phase
150 participants
Enrollment target
1
Study location

Study Summary

Single-center, prospective, 2:1 randomized controlled parallel-group study, with an open label extension to evaluate SomaSignal Informed Medical Management (informed) versus Standard of Care (uninformed).

Conditions Studied

Type 2 Diabetes

Interventions

  • OTHER SomaSignal Cardiovascular Risk in Type 2 Diabetes (CVD-T2D) Test and SomaSignal Metabolic Factors test

Study Locations (1)

Ohio

  • University Hospitals - Cleveland

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2022-01-26
Est. Completion 2023-03-31
Phase NA

Sponsor

University Hospitals Cleveland Medical Center

230 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05182359

The ClinicalTrials.gov registry entry for NCT05182359 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (86% lower). The listed sponsor is University Hospitals Cleveland Medical Center, which has 230 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which SomaSignal Cardiovascular Risk in Type 2 Diabetes (CVD-T2D) Test and SomaSignal Metabolic Factors test is the first listed.

NCT05182359 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT05182359 about?

NCT05182359 is a clinical study titled "Pragmatic Impact of Proteomic Risk Stratification in Diabetes Mellitus". Single-center, prospective, 2:1 randomized controlled parallel-group study, with an open label extension to evaluate SomaSignal Informed Medical Management (informed) versus Standard of Care (uninformed).

What is the current status of trial NCT05182359?

This trial is currently completed. It is a NA study. The enrollment target is 150 participants. The study started on 2022-01-26. Estimated completion is 2023-03-31.

What conditions does trial NCT05182359 study?

This clinical trial studies the following conditions: Type 2 Diabetes.

What interventions are being tested in trial NCT05182359?

The interventions under investigation include: SomaSignal Cardiovascular Risk in Type 2 Diabetes (CVD-T2D) Test and SomaSignal Metabolic Factors test (OTHER).

Who is sponsoring clinical trial NCT05182359?

This trial is sponsored by University Hospitals Cleveland Medical Center, which has 230 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05182359 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Type 2 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Type 2 Diabetes

All registered trials for this condition

Ohio

All trials with a study site in Ohio

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.